• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 - Research and Markets

    Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 - Research and Markets

  2. Sanofi 2Q Net Profit Down 10% at EUR1.04 Billion

    Sanofi 2Q Net Profit Down 10% at EUR1.04 Billion

  3. Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance

    Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance

  4. Back to Basics

    This screen finds stocks that would make it into Morningstar's Wide-Moat Focus strategy.

12345

©2017 Morningstar Advisor. All right reserved.